PNS64 Canadian Pricing and Reimbursement: Understanding the Biggest Hurdles in the Payer Landscape

2021 ◽  
Vol 24 ◽  
pp. S184
Author(s):  
R. Macaulay
Keyword(s):  
Pricing And Reimbursement

scholarly journals A global perspective on the issue of access to insulin

Diabetologia ◽  
2021 ◽  
Author(s):  
David Beran ◽  
Maria Lazo-Porras ◽  
Camille M. Mba ◽  
Jean Claude Mbanya
Keyword(s):  
Type 1 Diabetes ◽  
Diabetes Management ◽  
Multinational Companies ◽  
Global Perspective ◽  
Patient Access ◽  
Middle Income ◽  
Middle Income Countries ◽  
Wide Range ◽  
Pricing And Reimbursement

AbstractThe discovery of insulin in 1921 changed the prognosis for people with type 1 diabetes. A century later, availability and affordability of insulin remain a challenge in many parts of the globe. Using the WHO’s framework on understanding the life cycle of medicines, this review details the global and national challenges that affect patients’ abilities to access and afford insulin. Current research and development in diabetes has seen some innovations, but none of these have truly been game-changing. Currently, three multinational companies control over 95% of global insulin supply. The inclusion of insulin on the WHO’s Prequalification Programme is an opportunity to facilitate entry of new companies into the market. Many governments lack policies on the selection, procurement, supply, pricing and reimbursement of insulin. Moreover, mark-ups in the supply chain also affect the final price to the consumer. Whilst expenses related to diabetes are mostly covered by insurance in high-income countries, many patients from low- and middle-income countries have to pay out of their own pockets. The organisation of diabetes management within the healthcare system also affects patient access to insulin. The challenges affecting access to insulin are complex and require a wide range of solutions. Given that 2021 marks the centenary of the discovery of insulin, there is need for global advocacy to ensure that the benefits of insulin and innovations in diabetes care reach all individuals living with diabetes. Graphical abstract

scholarly journals Drug pricing and reimbursement decision making systems in Mongolia

2017 ◽  
Vol 10 (1) ◽  
Author(s):  
Gereltuya Dorj ◽  
Bruce Sunderland ◽  
Tsetsegmaa Sanjjav ◽  
Gantuya Dorj ◽  
Byambatsogt Gendenragchaa
Keyword(s):  
Decision Making ◽  
Reimbursement Decision ◽  
Drug Pricing ◽  
Pricing And Reimbursement

scholarly journals PHP137 Changes in the Medicines Pricing and Reimbursement Approach in Bulgaria

2012 ◽  
Vol 15 (7) ◽  
pp. A313
Author(s):  
I. Nikolov ◽  
M. Marcheva ◽  
D. Marinov ◽  
S. Georgieva ◽  
G. Petrova
Keyword(s):  
Pricing And Reimbursement

scholarly journals PBI44 Advanced Therapies: New Challenge for the Italian Pricing and Reimbursement System

2020 ◽  
Vol 23 ◽  
pp. S417-S418
Author(s):  
G. Caffarelli ◽  
A. Russo ◽  
M. Ferrario ◽  
N. Panzeri ◽  
G. Giuliani
Keyword(s):  
Reimbursement System ◽  
Advanced Therapies ◽  
Pricing And Reimbursement

scholarly journals Addressing the medicines access challenge through balance, evidence, collaboration and transparency: key take-away lessons of the 4th PPRI Conference

2021 ◽  
Vol 14 (1) ◽  
Author(s):  
Sabine Vogler ◽  
Nina Zimmermann ◽  
Zaheer-Ud-Din Babar ◽  
Reinhard Busse ◽  
Jaime Espin ◽  
...  
Keyword(s):  
Best Practice ◽  
Access To Medicines ◽  
Health Technologies ◽  
Relevant Evidence ◽  
Practice Models ◽  
The Future ◽  
Pricing And Reimbursement ◽  
Multi Stakeholder

AbstractThe 4th PPRI Conference, held in Vienna in October 2019, addressed issues related to equitable and affordable access to medicines. A multi-stakeholder audience from around the globe discussed solutions and best practice models for current challenges such as high-priced medicines, limitations of current pricing and reimbursement policies and tight budgets for health technologies. A multi-faceted approach (so-called balance, evidence, collaboration and transparency/BECT strategy) was also discussed. This includes an improved balance of different interests and policy areas, generation of relevant evidence, collaboration between countries and stakeholders, and transparency, and was considered as the most promising pathway for the future.

Sign in / Sign up

Export Citation Format

Share Document